 |
Email:
|
peter.solar@upjs.sk |
|
Homepage:
|
https://www.upjs.sk/LF/zamestnanec/peter.solar | |
|
Faculty:
|
LF UPJŠ
-
Pavol Jozef Šafárik University in Košice Faculty of Medicine
|
|
|
Department:
|
ULBL
-
Department of Medical Biology
|
|
|
Office:
|
MB3P24 | |
|
Phone:
|
+421 55 234 3278 | |
|
ORCID ID:
|
0000-0002-1287-2979 |
|
Profile courses
|
|
Biológia 1, 2 - Všeobecné lekárstvo, I., II. degree
|
|
Biology 1, 2 - General Medicine, I., II. degree
|
|
Medical and human biology 1, 2 - Dental Medicine, I., II. degree
|
|
Lekárska a humánna biológia 1, 2 - Zubné lekárstvo, I., II. degree
|
|
Selected publications
|
|
ADC - Solárová Z., Mojžiš J., Solár P., Hsp90 inhibitor as a sensitizer of cancer cells to different therapies, Int. J. Oncol. 46 (2015) 907-926. IF 3.9, Q2. Cited: 54 times |
|
ADC- Kimáková P., Solár P., Solárová Z., Komel R., Debeljak N., Erythropoietin and its angiogenic activity, Int. J. Mol. Sci. 18 (2017), art.no. 1519. IF 4.6, Q1. Cited: 45 times |
|
ADC - Kubatka P., Uramová S., Kello M., Kajo K., Kružliak P., Mojžiš J., Výbohová D., Adamkov M., Jašek K., Lasabová Z., Žubor P., Fialová S., Dokupilová S., Solár P., Péč M., Adamicová K., Danko J., Adamek M., Busselberg D., Antineoplastic effects of clove buds (Syzygium aromaticum L.) in the model of breast carcinoma, J. Cell. Mol. Med. 21 (2017) 2837 - 2851. IF 4.5, Q1. Cited: 41 times |
|
ADC - Kapinová A., Kubátka P., Golubnitschaja O., Kello M., Žubor P., Solár P., Péč M., Dietary phytochemicals in breast cancer research: anticancer effects and potential utility for effective chemoprevention, Environ. Health Prevent. Med. 23 (2018) 1-18. IF 2.2, Q2. Cited 68 times |
|
ADM - Uramová S., Kubatka P., Danková Z., Kapinová A., Zoľáková B., Samec M., Žubor P., Zulli A., Valentová V., Kwon T., Solár P., Kello M., Kajo K., Busselberg D., Péč M.-, Danko J., Plant natural modulators in breast cancer prevention: status quo and future perspectives reinforced by predictive, preventive, and personalized medical approach, d 9 (2018) 403-419. IF 4.8, Q1. Cited: 26 times |
|
Selected projects
|
|
VEGA 1/0394/15: Erythropoietin receptor in mammary adenocarcinoma and its role in tamoxifen resistance, grant project leader. |
|
VEGA 1/0536/19: The role of the erythropoietin receptor in the response of mammary adenocarcinoma cells to paclitaxel in vitro and in vivo, leader of the grant project. |
|
ASFEU project: "Innovation of the technological process of preparation of the immunomodulatory preparation Transfer factor, verification of its effectiveness, safety and composition" (ITMS code 26220220157), leader and project manager. |
|
International mobilities and visits
|
|
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA, 2002 - 2003, postdoc stay
|
|
University of Ljubljana, Ljubljana, Slovenia, 1.7.2019 - 6.7.2019, Erasmus+
|
|
Awards
|
|
2007 - Avon Scholar Award: American Association for Cancer Research Conference
|
|
Projects
|
|
2005-2007 Slovenská agentúra pre podporu vedy a výskumu
APVV-20-012104: "The influence of erythropoietin on the growth of tumours in vitro and in vivo" 2006-2008 Vedecká grantová agentúra Ministersta školstva a Slovenskej akadémie vied VEGA 1/3253/06: "Molecular and biological substance of erythropoietin undesirable effect in the therapy of cancer cell" |
|
International collaboration
|
|
Institute of Biophysics, Czech Academy of Sciences, Brno, Czech Republic
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia |
